COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,681 Articles (22,913 medRxiv, 8,768 bioRxiv)

Most recent first Previous |  Page 605: Articles 6041-6050  | Next

Fc-gamma receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2
Mackin, S. R., Desai, P., Whitener, B. M., Karl, C. E., Liu, M., Baric, R. S., Edwards, D. K., Chicz, T. M., McNamara, R. P., Alter, G., Diamond, M. S.
10.1101/2022.11.27.518117 — Posted: 2022-11-29
Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination
Adams, L. E., Leist, S. R., Dinnon, K. H., West, A., Gully, K. L., Anderson, E., Loome, J. F., Madden, E., Powers, J., Schaefer, A., Sarkar, S., Castillo, I., Maron, J., McNamara, R. P., Bertera, H. L., Zweigart, M. R., Higgins, J. S., Hampton, B. K., Lakshmanane, P., Alter, G., Montgomery, S., Baxter, V., Heise, M. T., Baric, R. S.
10.1101/2022.11.28.518175 — Posted: 2022-11-28
Extracellular disintegration of viral proteins as an innovative strategy for developing broad-spectrum antivirals against coronavirus
Sun, K., Ding, Z., Jia, X., Cheng, H., Li, Y., Wu, Y., Li, Z., Huang, X., Pu, F., Li, E., Wang, G., Wang, W., Ding, Y., Wong, G., Chiu, S., Lan, J., Hu, A.
10.1101/2022.11.24.517008 — Posted: 2022-11-28
SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
Boschi, C., Scheim, D. E., Bancod, A., Millitello, M., Le Bideau, M., Colson, P., Fantini, J., La Scola, B.
10.1101/2022.11.24.517882 — Posted: 2022-11-28
Highly potent antisense oligonucleotides (ASOs) targeting the SARS-CoV-2 RNA genome
Dauksaite, V., Tas, A., Wachowius, F., Spruit, A., van Hemert, M., Snijder, E., van der Veer, E. P., van Zonneveld, A. J.
10.1101/2022.11.28.518195 — Posted: 2022-11-28
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J., Valdez, R., Lauring, A. S., Sheng, Z., Wang, H. H., Gordon, A., Liu, L., Ho, D. D.
10.1101/2022.11.23.517532 — Posted: 2022-11-28
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ1.1 and XBB.
Sullivan, D. J., Franchini, M., Senefeld, J., Joyner, M., Casadevall, A., Focosi, D.
10.1101/2022.11.25.517977 — Posted: 2022-11-28
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein
Kim, Y., Jackobsen, H., Fuerholzner, B., Eschke, K., Hoffmann, M., Chaudhry, M. Z., Bertoglio, F., Hust, M., Widera, M., Ciesek, S., Poehlmann, S., Cicin-Sain, L.
10.1101/2022.11.25.517953 — Posted: 2022-11-28
Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2
Bianchini, F., Crivelli, V., Abernathy, M. E., Guerra, C., Palus, M., Muri, J., Marcotte, H., Piralla, A., Pedotti, M., De, R., Simonelli, L., Matkovic, M., Toscano, C., Biggiogero, M., Calvaruso, V., Svoboda, P., Cervantes Rincon, T., Fava, T., Podesvova, L., Shanbhag, A. A., Celoria, A., Sgrignani, J., Stefanik, M., Hoenig, V., Pranclova, V., Michalcikova, T., Prochazka, J., Guerrini, G., Mehn, D., Ciabattini, A., Abolhassani, H., Jarrossay, D., Uguccioni, M., Medaglini, D., Pan-Hammarstroem, Q., Calzolai, L., Fernandez, D., Baldanti, F., Franzetti-Pellanda, A., Garzoni, C., Sedlacek, R., Ruzek, D., Varani, L., Cavalli, A., Barnes, C. O., Robbiani, D. F.
10.1101/2022.11.24.515932 — Posted: 2022-11-28
Strengthening response coordination through public health emergency operations centers in Africa: Lessons learned from 56-week webinar sessions, 2020-2021
Eteng, W., Gebrewahid, A. L., Tekeste, S., Mankoula, W., Collard, E., Waya, C., Rosenfeld, E., Wilton, C. M., Muita, M., McGinley, L., Kawe, Y., Abdullah, A., Halm, A., Li, J., Lokossou, V. L., Kanoute, Y., Sonko, I., Aragaw, M.
10.1101/2022.11.22.22282627 — Posted: 2022-11-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).